NASDAQ: GLUE
Monte Rosa Therapeutics Inc Stock Ownership - Who owns Monte Rosa Therapeutics?

Insider buying vs selling

Have Monte Rosa Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Edmund DunnPrincipal Accounting Officer2025-06-032,062$4.45
$9.17kSell
Chandra P. LeoDirector2025-03-2410,000$5.84
$58.38kBuy

1 of 1

GLUE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GLUE insiders and whales buy or sell their stock.

GLUE Shareholders

What type of owners hold Monte Rosa Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bradley J. Phd Bolzon14.46%8,897,053$114.33MInsider
Versant Venture Capital VI LP12.60%7,750,860$99.60MInsider
New Enterprise Associates 17 LP12.51%7,692,298$98.85MInsider
Ali Behbahani12.51%7,692,298$98.85MInsider
Forest Baskett12.51%7,692,298$98.85MInsider
Carmen Chang12.51%7,692,298$98.85MInsider
Anthony A. Florence Jr.12.51%7,692,298$98.85MInsider
Liza Landsman12.51%7,692,298$98.85MInsider
Mohamad Makhzoumi12.51%7,692,298$98.85MInsider
Nea Management Company LLC12.51%7,692,298$98.85MInstitution

1 of 3

GLUE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GLUE34.03%65.97%Net Buying
YDES0.00%3.67%
MRVI45.32%54.68%Net Buying
GERN80.63%1.09%Net BuyingNet Buying
NKTR23.75%76.25%Net SellingNet Selling

Monte Rosa Therapeutics Stock Ownership FAQ

Who owns Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ: GLUE) is owned by 101.12% institutional shareholders, 196.06% Monte Rosa Therapeutics insiders, and 0.00% retail investors. Bradley J. Phd Bolzon is the largest individual Monte Rosa Therapeutics shareholder, owning 8.90M shares representing 14.46% of the company. Bradley J. Phd Bolzon's Monte Rosa Therapeutics shares are currently valued at $114.33M.

If you're new to stock investing, here's how to buy Monte Rosa Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.